Draft:Genesis Molecular AI

Genesis Molecular AI, Inc. is a private artificial intelligence (AI) company headquartered in the San Francisco Bay Area, with locations in San Mateo, San Diego and New York. Founded in 2019, the company is developing generative and predictive artificial intelligence technologies for the discovery of small molecule drugs. ^[1]

Genesis (formerly Genesis Therapeutics), was founded in 2019 by Evan Feinberg. The company emerged from Feinberg's work with Vijay S. Pande at Stanford University, where they developed artificial intelligence methods for drug discovery and were early pioneers of graph neural networks (GNN’s) for molecules. This work included PotentialNet, a family of spatial graph convolutional deep learning algorithms in Vijay S. Pande’s lab.^{[2] [3]}

Since its founding, Genesis has raised over $300 million.^[2] In 2020, the company announced a $52M Series A led by Rock Springs Capital.^[4] In 2023, the company raised an oversubscribed $200M Series B, co-led by Andreessen Horowitz.^[5] Genesis has been recognized in the Forbes AI 50 list in 2020, 2021 and 2022. ^{[6] [7] [8]} It was also listed on the Fierce Medtech's Fierce 15 list in 2023 and on CB Insights AI 100: The top AI companies in 2024.^{[9] [10]}

Genesis’ platform, called Genesis Exploration of Molecular Space (GEMS), uses novel AI systems, including diffusion models, multi-task ADME models, language models, and physical simulations to generate drug candidates across multiple therapeutic areas by optimizing small molecules for complex targets.^{[11] [12]}

In 2025 with co-authorship from NVIDIA, Genesis announced Pearl (Placing Every Atom in the Right Location),^[13] a foundation model for biomolecular structure prediction. Pearl predicts 3D protein–ligand complex structures through a SO(3)-equivariant diffusion model trained on both experimental and synthetic protein-ligand complexes. The authors of Pearl report that it was the first to outperform Google DeepMind’s AlphaFold 3 model on certain benchmarks. ^[13]

Genesis Molecular AI has entered into multiple collaborations with major pharmaceutical and technology companies, including: